Overview

A DRF Study to Evaluate Safety, Tolerability, PK, and Activity of Oradoxel Monotherapy in Subjects w Adv. Malignancies

Status:
Unknown status

Trial end date:
2020-04-30

Target enrollment:

Participant gender:

Summary

This is a nonrandomized, open-label, dose escalation, safety, activity, and PK study to determine the MTD and optimal dosing regimen of Oradoxel. No control group has been included.

Phase:

Phase 1

Details

Lead Sponsor:

Athenex, Inc.
Kinex Pharmaceuticals Inc

Treatments:

Docetaxel